MARKET

HOTH

HOTH

Hoth Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.860
-0.030
-1.04%
Pre Market: 2.830 -0.03 -1.05% 08:32 06/02 EDT
OPEN
2.820
PREV CLOSE
2.890
HIGH
2.880
LOW
2.790
VOLUME
334.10K
TURNOVER
--
52 WEEK HIGH
9.07
52 WEEK LOW
2.595
MARKET CAP
33.16M
P/E (TTM)
-3.2953
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average HOTH stock price target is 9.00 with a high estimate of 10.00 and a low estimate of 7.00.

EPS

HOTH News

More
Hoth Therapeutics Announces Closing of Public Offering of Common Stock
PR Newswire · 5d ago
71 Biggest Movers From Friday
Gainers Inari Medical, Inc. (NASDAQ: NARI) shares surged 123.7% to close at $42.51 on Friday after pricing its IPO on Friday.
Benzinga · 05/26 08:30
46 Stocks Moving In Friday's Mid-Day Session
Gainers Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) shares jumped 98.40% to $2.5201 after the company announced positive preliminary results from the second interim analysis of its ongoing NAV3-31 Phase 2B study.
Benzinga · 05/22 16:45
FL, HPE among premarket losers
Seeking Alpha - Article · 05/22 13:19
Hoth Therapeutics Announces the Appointment of Michael Peters, Ph.D. to Scientific Advisory Board
PR Newswire · 05/22 13:00
30 Stocks Moving in Friday's Pre-Market Session
Gainers Navidea Biopharmaceuticals, Inc. (NASDAQ: NAVB) shares rose 65.2% to $2.18 in pre-market trading after the company reported results of second interim analysis of ongoing Phase 2B study in rheumatoid arthritis.
Benzinga · 05/22 11:18
Hoth Therapeutics Prices Underwritten Public Offering of 1.8M Shares at $2.75/Share
Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ: HOTH) today announced the pricing of an underwritten public offering of 1,818,182 shares of common stock at a public offering price of $2.75 per share, before underwriting discounts and commissions.
Benzinga · 05/22 01:21
Hoth Announces Proposed Public Offering of Common Stock
PR Newswire · 05/21 21:01

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About HOTH

Hoth Therapeutics, Inc. is a development stage biopharmaceutical company focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema. The Company is engaged in developing and commercializing the BioLexa Platform. BioLexa Platform is a proprietary, patented antimicrobial therapy. The BioLexa Platform traps all the zinc ions by adding a chelator called DTPA, which prevents Staph biofilm formation. It intends to explore the use of the BioLexa Platform for the treatment of atopic dermatitis, or eczema. It also focuses on exploring the use of the BioLexa Platform in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures.
More

Webull offers kinds of Hoth Therapeutics Inc stock information, including NASDAQ:HOTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HOTH stock news, and many more online research tools to help you make informed decisions.